Drug, device firms concerned over comparative-effectiveness studies

04/13/2009 | Wall Street Journal, The

Drugmakers and medical-device companies are concerned that studies comparing the cost effectiveness of treatments will be used to deny patients access to the best care available. "The overarching purpose of the program is to give clinicians and patients information they need to make decisions," including data on effectiveness, safety and costs, said Dr. Carolyn Clancy, director of the Agency for Healthcare Research and Quality.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care